Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety (NCT00302744) | Clinical Trial Compass
CompletedPhase 1/2
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
United States12 participantsStarted 2004-04
Plain-language summary
Psychiatric Research Study For Cancer Patients
The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Have advanced-stage cancer and anxiety.
* Be between the ages of 18 - 70.
Note: The location for the two treatment sessions is Los Angeles, California. Treatment sessions are scheduled three to six weeks apart, and they include one overnight hospital stay both times.
Exclusion Criteria:
* Not have cancer that affects the central nervous system or brain function.
* Have no history of major psychiatric disorder.
* Have no kidney disease, abnormal liver functions, epilepsy, or cardiovascular disease, including untreated hypertension.
* Not be taking insulin, oral hypoglycemic, anti-seizure, or cardiovascular medications (except anti-hypertensive drugs).
* May take PRN benzodiazepines up to 3 days before the session.
* No Prozac for the previous 5 weeks.
* No medications the day of and the day after treatment sessions, except may take ongoing adjuvant chemotherapy as prescribed, prescribed or over-the-counter non-narcotic pain medication at any time, and narcotic pain medications up to eight hours before administration of psilocybin and six hours after administration.
* No alcohol consumption the day before, the day of, and the day after a session.
* Female subjects of childbearing potential must have a negative pregnancy test and agree to use an effective form of birth control.
What they're measuring
1
Anxiety
Timeframe: 6 months
Trial details
NCT IDNCT00302744
SponsorLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center